- Home
- CTSO vs BDL Comparison
CTSO vs BDL Comparison
Compare CTSO & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTSO
- BDL
- Stock Information
- Founded
- CTSO 1997
- BDL 1959
- Country
- CTSO United States
- BDL United States
- Employees
- CTSO N/A
- BDL N/A
- Industry
- CTSO Medical/Dental Instruments
- BDL Restaurants
- Sector
- CTSO Health Care
- BDL Consumer Discretionary
- Exchange
- CTSO Nasdaq
- BDL Nasdaq
- Market Cap
- CTSO 52.6M
- BDL 60.8M
- IPO Year
- CTSO N/A
- BDL N/A
- Fundamental
- Price
- CTSO $1.18
- BDL $30.70
- Analyst Decision
- CTSO Buy
- BDL
- Analyst Count
- CTSO 2
- BDL 0
- Target Price
- CTSO $5.50
- BDL N/A
- AVG Volume (30 Days)
- CTSO 99.9K
- BDL 2.9K
- Earning Date
- CTSO 08-12-2025
- BDL 08-12-2025
- Dividend Yield
- CTSO N/A
- BDL 1.79%
- EPS Growth
- CTSO N/A
- BDL 14.76
- EPS
- CTSO N/A
- BDL 2.18
- Revenue
- CTSO $35,332,238.00
- BDL $198,785,000.00
- Revenue This Year
- CTSO $18.34
- BDL N/A
- Revenue Next Year
- CTSO $19.82
- BDL N/A
- P/E Ratio
- CTSO N/A
- BDL $14.09
- Revenue Growth
- CTSO 15.37
- BDL 9.31
- 52 Week Low
- CTSO $0.70
- BDL $22.61
- 52 Week High
- CTSO $1.61
- BDL $35.98
- Technical
- Relative Strength Index (RSI)
- CTSO 67.21
- BDL 62.09
- Support Level
- CTSO $1.03
- BDL $29.41
- Resistance Level
- CTSO $1.29
- BDL $35.98
- Average True Range (ATR)
- CTSO 0.09
- BDL 1.39
- MACD
- CTSO 0.02
- BDL -0.20
- Stochastic Oscillator
- CTSO 75.45
- BDL 33.08
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
About BDL Flanigan's Enterprises Inc.
Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.